Over the past two decades, cannabis potency has surged in Canada, with tetrahydrocannabinol (THC) concentrations rising from approximately 4% to 20% in most legal dried cannabis.

Dr. Nicholas Fabiano, a researcher from the University of Ottawa, highlights that this increase in cannabis potency is likely contributing to a stronger link between cannabis use and schizophrenia.

Regular use of high-potency cannabis is particularly concerning, as it is associated with a greater risk of developing psychosis, especially among younger males and those with a history of mental health disorders.

A significant study involving nearly 9.8 million people in Ontario found that individuals visiting emergency departments for cannabis use face a staggering 14.3-fold increased risk of schizophrenia-spectrum disorders, with those experiencing cannabis-induced psychosis at a 241.6-fold increased risk.

Treatment for cannabis-induced psychosis typically involves stopping cannabis use, and in severe cases, may require antipsychotic medication to manage prolonged symptoms.

Behavioral interventions, such as motivational interviewing and cognitive behavioral therapy, can be effective in helping individuals overcome cannabis cravings and adhere to treatment plans.

The heightened risk of psychosis associated with high-potency cannabis use is particularly pronounced among frequent users, younger individuals, and males.